Mereo BioPharma
MREO
14 hedge funds and large institutions have $3.42M invested in Mereo BioPharma in 2020 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
1.36% more ownership
Funds ownership: 1.27% → 2.64% (+1.4%)
0% more funds holding
Funds holding: 14 → 14 (0)
16% less capital invested
Capital invested by funds: $4.08M → $3.42M (-$662K)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Boxer Capital
San Diego,
California
|
+$4.24M |
| 2 |
CL
CSS LLC
Chicago,
Illinois
|
+$39K |
| 3 |
WAM
Wealthspire Advisors (Maryland)
Potomac,
Maryland
|
+$24.7K |
| 4 |
WANY
Wealthspire Advisors (New York)
New York
|
+$24.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$414K |
| 2 |
Primecap Management
Pasadena,
California
|
-$101K |
| 3 |
State Street
Boston,
Massachusetts
|
-$54K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$8.91K |
| 5 |
Morgan Stanley
New York
|
-$2.97K |
MREO Hedge Fund Activity: Q1 2020 in Review
14 of the 4,547 institutional investors tracked by Wall St. Rank reported a position in Mereo BioPharma (MREO) for Q1 2020, worth a combined $3.42M — down 16% from $4.08M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new MREO positions and 2 closed out — a net gain of 1 holder — while 1 added to existing stakes and 3 trimmed.
The largest buyer was Boxer Capital, opening a new position worth an estimated $4.24M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $414K sold.
- 14 institutional investors held Mereo BioPharma (MREO) as of Q1 2020, unchanged from Q4 2019.
- Funds reported $3.42M of Mereo BioPharma stock for Q1 2020, down 16% quarter-over-quarter.
- 3 funds opened new Mereo BioPharma positions in Q1 2020 and 2 closed out, a net change of +1 holder.
- The largest Mereo BioPharma buyer in Q1 2020 was Boxer Capital, an estimated $4.24M added.
- The largest Mereo BioPharma seller in Q1 2020 was Renaissance Technologies, an estimated $414K sold.
Based on aggregated 13F filings for Q1 2020.